GlassScriptPhysician profile
Sherry A Davis
NPI 1184820128
$4,587.84
in general payments reported to CMS, 2019-2025
46 companies · $971 in 2025
The $971 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,004 · 2022: $1,013 · 2023: $750 · 2024: $850 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,570.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $408.93 | 2021-2025 | |
| Abbvie INC. | $392.79 | 2022-2025 | |
| Glaxosmithkline, LLC. | $246.24 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $225.71 | 2021-2023 | Imbruvica, Epkinly |
| Amgen INC. | $224.44 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Merck Sharp & Dohme LLC | $206.15 | 2021-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $197.35 | 2021-2025 | |
| Janssen Biotech, INC. | $168.88 | 2021-2025 | Rybrevant, Darzalex, Talvey |
| Daiichi Sankyo INC. | $142.21 | 2022-2025 | Enhertu, Datroway |
| Incyte Corporation | $137.03 | 2021-2025 | Jakafi, Monjuvi, Jakafi |
| Seagen INC. | $133.18 | 2021-2023 | Adcetris |
| Astellas Pharma US INC | $132.92 | 2021-2025 | Xtandi, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $128.34 | 2021-2024 | Iclusig |
| Gilead Sciences, INC. | $119.89 | 2022-2024 | Trodelvy |
| Puma Biotechnology, INC. | $116.42 | 2021-2023 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $116.13 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $115.47 | 2021-2024 | |
| Celgene Corporation | $109.08 | 2021-2024 | Reblozyl |
| Genentech USA, INC. | $109.03 | 2022-2025 | Polivy, Lunsumio, Columvi |
| Astrazeneca Pharmaceuticals LP | $105.30 | 2021-2025 | Calquence, Enhertu |
| Pfizer INC. | $91.97 | 2021-2025 | |
| Array Biopharma INC | $89.82 | 2021-2024 | Braftovi, Tukysa, Mektovi |
| Pharmaessentia USA Corporation | $76.73 | 2022-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $73.48 | 2022-2025 | |
| Tersera Therapeutics LLC | $60.84 | 2023-2025 | Zoladex, Xermelo |
| Morphosys, US INC. | $58.06 | 2021-2023 | Monjuvi |
| Blueprint Medicines Corporation | $55.68 | 2023-2025 | Ayvakit |
| Emd Serono, INC. | $50.19 | 2021-2023 | Tepmetko |
| Deciphera Pharmaceuticals INC. | $48.81 | 2021-2025 | Romvimza, Qinlock |
| Geron Corporation | $45.16 | 2024-2025 | Rytelo |
| Beigene USA, INC. | $42.28 | 2024 | Brukinsa |
| Exelixis INC. | $42.10 | 2021-2023 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $31.98 | 2021-2022 | |
| Foundation Medicine, INC. | $27.46 | 2021 | |
| Aveo Pharmaceuticals, INC. | $25.18 | 2023 | Fotivda |
| Alexion Pharmaceuticals, INC. | $24.74 | 2021-2023 | Ultomiris |
| Fennec Pharmaceuticals, INC. | $24.46 | 2024 | Pedmark |
| Azurity Pharmaceuticals, INC. | $23.25 | 2025 | Danziten |
| Taiho Oncology, INC. | $23.23 | 2024 | |
| Beone Medicines USA, INC. | $22.74 | 2025 | Brukinsa |
| Tolmar Pharmaceuticals, INC. | $22.70 | 2021 | |
| Adaptive Biotechnologies Corporation | $22.68 | 2025 | Clonoseq |
| Teleflex LLC | $21.06 | 2023 | Langston |
| Jazz Pharmaceuticals INC. | $20.52 | 2024 | |
| Myriad Genetic Laboratories, INC. | $14.61 | 2021 | |
| Edwards Lifesciences Corporation | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.